Scarica l'app Stockscreener
9.425
4.30%
0.345
Precedente Chiudi:
$9.08
Aprire:
$9.44
Volume 24 ore:
52,766
Relative Volume:
0.16
Capitalizzazione di mercato:
$583.12M
Reddito:
$36.90M
Utile/perdita netta:
$-166.28M
Rapporto P/E:
-2.8647
EPS:
-3.29
Flusso di cassa netto:
$-203.53M
1 W Prestazione:
+12.47%
1M Prestazione:
+17.64%
6M Prestazione:
-58.30%
1 anno Prestazione:
-61.64%
Intervallo 1D:
$9.22
$9.5499
Intervallo di 1 settimana:
$7.945
$9.5499
Portata 52W:
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Nome
Bicycle Therapeutics Plc Adr
Settore
Industria
Telefono
011441223261503
Indirizzo
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Confronta BCYC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
9.46 | 583.12M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.90 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.10 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
650.09 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.20 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.53 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Iniziato | Stephens | Equal-Weight |
| 2024-09-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Iniziato | Cowen | Outperform |
| 2022-07-28 | Iniziato | Barclays | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-04-13 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | SVB Leerink | Outperform |
| 2021-12-09 | Iniziato | Needham | Buy |
| 2021-09-30 | Iniziato | B. Riley Securities | Buy |
| 2021-04-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Iniziato | Oppenheimer | Outperform |
| 2020-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-09-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-06-17 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-17 | Iniziato | Goldman | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
| 2019-06-17 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Bicycle Therapeutics Plc Adr Borsa (BCYC) Ultime notizie
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock hits 52-week low at $11.14 By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics Plc Adr Azioni (BCYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bicycle Therapeutics Plc Adr Azioni (BCYC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Apr 03 '25 |
Sale |
7.48 |
1,038 |
7,764 |
121,870 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Apr 02 '25 |
Sale |
8.02 |
814 |
6,528 |
122,908 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 03 '25 |
Sale |
7.48 |
3,432 |
25,671 |
486,265 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 02 '25 |
Sale |
8.02 |
2,237 |
17,941 |
489,697 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Apr 02 '25 |
Sale |
8.02 |
1,133 |
9,087 |
98,655 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Apr 03 '25 |
Sale |
7.48 |
1,038 |
7,764 |
97,617 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Apr 02 '25 |
Sale |
8.02 |
467 |
3,745 |
54,813 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Apr 03 '25 |
Sale |
7.48 |
266 |
1,990 |
54,547 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Apr 02 '25 |
Sale |
8.02 |
210 |
1,684 |
31,936 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Apr 03 '25 |
Sale |
7.48 |
109 |
815 |
31,827 |
0.01%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):